Omphalocele
ORPHA:660Morphological anomalyNot applicableAntenatal
Фенотипы (HPO)5
Очень частый (80–99%)4
HP:0001539Omphalocele
HP:0001622Premature birth
HP:0011425Fetal ultrasound soft marker
HP:0011432Elevated maternal circulating alpha-fetoprotein concentration
Частый (30–79%)1
HP:0002091Restrictive ventilatory defect
Эпидемиология43
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Prevalence at birth | 1-5 / 10 000 | 11.7 | Europe | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Europe | Class only |
| Prevalence at birth | 1-5 / 10 000 | 19.6 | Austria | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Austria | Class only |
| Prevalence at birth | 1-5 / 10 000 | 14.6 | Belgium | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Belgium | Class only |
| Prevalence at birth | 1-5 / 10 000 | 10.9 | Croatia | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Croatia | Class only |
| Prevalence at birth | 1-5 / 10 000 | 19.8 | Denmark | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Denmark | Class only |
| Prevalence at birth | 1-5 / 10 000 | 13.6 | France | Value and class |
| Point prevalence | 1-5 / 10 000 | — | France | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11.6 | Germany | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Germany | Class only |
| Prevalence at birth | 1-9 / 100 000 | 6.6 | Hungary | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Hungary | Class only |
| Prevalence at birth | 1-5 / 10 000 | 25.3 | Ireland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Ireland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11 | Italy | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Italy | Class only |
| Prevalence at birth | 1-5 / 10 000 | 48.2 | Malta | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Malta | Class only |
| Prevalence at birth | 1-5 / 10 000 | 22.9 | Netherlands | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Netherlands | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11.2 | Norway | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Norway | Class only |
| Prevalence at birth | 1-5 / 10 000 | 12.1 | Poland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Poland | Class only |
| Prevalence at birth | 1-9 / 100 000 | 6.9 | Spain | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Spain | Class only |
| Prevalence at birth | 1-5 / 10 000 | 12.3 | Switzerland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Switzerland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11.6 | United Kingdom | Value and class |
| Point prevalence | 1-5 / 10 000 | — | United Kingdom | Class only |
| Prevalence at birth | 1-5 / 10 000 | 16.2 | Ukraine | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Ukraine | Class only |
| Prevalence at birth | 1-5 / 10 000 | 10 | Czech Republic | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Czech Republic | Class only |
| Prevalence at birth | 1-9 / 100 000 | 6.3 | Japan | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Japan | Class only |
| Prevalence at birth | 1-5 / 10 000 | 15.2 | China | Value and class |
| Prevalence at birth | 1-5 / 10 000 | 18.6 | United States | Value and class |
| Point prevalence | 1-5 / 10 000 | — | United States | Class only |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)